What impression statement should be documented for a patient who meets criteria for a major depressive episode of moderate severity, without psychotic features, bipolar spectrum signs, or significant substance use, presenting with persistent low mood, anhedonia, fatigue, difficulty concentrating, and sleep disturbance for more than two weeks causing functional impairment, and who has no prior antidepressant trials or contraindications to first‑line pharmacotherapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Impression Statement for Depression

For a patient meeting criteria for a major depressive episode of moderate severity without psychotic features, bipolar spectrum signs, or significant substance use, document: "Major Depressive Disorder, single episode, moderate severity, without psychotic features."

Diagnostic Documentation Framework

The impression statement should capture four essential elements based on DSM-5 criteria:

1. Primary Diagnosis

  • State "Major Depressive Disorder" as the principal diagnosis
  • This patient meets the required threshold of ≥5 symptoms including the mandatory presence of either depressed mood or anhedonia, plus additional symptoms (fatigue, concentration difficulties, sleep disturbance) lasting >2 weeks with functional impairment 1

2. Episode Specification

  • Document as "single episode" since no prior antidepressant trials are mentioned, suggesting this is the first recognized episode
  • If there is history of prior episodes, specify "recurrent" instead, as this has significant treatment duration implications 2

3. Severity Designation

  • Specify "moderate severity" as stated in the clinical scenario
  • Moderate depression typically presents with the depressed mood criterion accompanied by somatic symptoms (fatigue, sleep disturbance, concentration difficulties), distinguishing it from severe depression which more commonly presents with anhedonia and non-somatic symptoms 3

4. Psychotic Features Status

  • Explicitly state "without psychotic features" to clarify the absence of delusions or hallucinations
  • This distinction is critical for treatment selection, as severe depression with psychotic features may require antidepressant-antipsychotic combination therapy 4

Additional Documentation Considerations

Rule Out Bipolar Spectrum

While the scenario states no bipolar spectrum signs are present, your documentation should reflect that this was actively assessed. The absence of:

  • Prior manic or hypomanic episodes
  • Family history of bipolar disorder
  • Psychomotor agitation or mood lability

This is crucial because misdiagnosis of bipolar disorder as unipolar depression occurs frequently and leads to inappropriate antidepressant monotherapy, which has little efficacy in bipolar depression 5, 6. Approximately 75% of symptomatic time in bipolar disorder consists of depressive episodes, making initial presentation indistinguishable from MDD 6.

Substance Use Exclusion

Document that symptoms are not attributable to substance use or general medical conditions (e.g., hypothyroidism), as required by diagnostic criteria 1.

Functional Impairment

Note the presence of functional impairment in social, occupational, or other important areas, as this distinguishes clinically significant depression from subsyndromal symptoms 7.

Treatment Implications of This Impression

This specific impression statement directly guides evidence-based treatment:

  • First episode, moderate severity → Initiate second-generation antidepressant selected based on adverse effect profile, cost, and patient preference (all SGAs have equivalent efficacy) 2
  • Treatment duration → Continue for 4-9 months after achieving remission for first episode 2
  • Monitoring schedule → Assess within 1-2 weeks of initiation for suicidality, then regularly for therapeutic response 2
  • Response timeline → Modify treatment if inadequate response by 6-8 weeks 2

Common Pitfall to Avoid

Do not document simply as "depression" or "depressive symptoms" without specifying episode type and severity. The distinction between first episode versus recurrent depression changes treatment duration recommendations from 4-9 months to potentially years or lifelong therapy 2. Similarly, severity classification affects whether psychotherapy alone, medication alone, or combination therapy is most appropriate 4.

Related Questions

In a 32-year-old woman with major depressive symptoms and a mother who has bipolar I disorder, what is the first pharmacologic treatment to trial?
What is the first-line medication for moderately severe depression?
What is the best psychiatric medication for a patient with bipolar I disorder and co-occurring pancreatitis?
What are the current treatment guidelines for bipolar disorder, including first‑line mood stabilizers, antipsychotics, dosing, and monitoring recommendations?
What is the appropriate evaluation and treatment plan for a female client with two months of depressive symptoms and a one‑month history of elevated mood, increased energy, and risky sexual behavior who is now severely depressed?
Does atenolol cause vivid or unpleasant dreams, and which beta‑blocker is associated with the lowest incidence of bad dreams?
What treatment regimen should be used for a patient with bone‑only metastatic breast cancer that is estrogen‑receptor (ER) and progesterone‑receptor (PR) positive, HER2‑negative, progressing on tamoxifen, when a CDK4/6 inhibitor is not affordable?
In a well‑appearing 5‑year‑old with two weeks of intermittent fever and a white‑cell count of 12.6 ×10⁹/L, should I start amoxicillin‑clavulanate (Augmentin) without a referral?
Which infectious disease is NOT predisposed by the anti‑CD20 monoclonal antibody rituximab (Rituxan)?
In a patient with thrombocytopenia confirmed with citrate anticoagulated sample, should follow‑up platelet counts always be performed using citrate?
When does pregnancy‑associated thrombocytopenia typically begin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.